Alpine Partners VI LLC acquired a new stake in Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) during the second quarter, Holdings Channel reports. The institutional investor acquired 40,162 shares of the company’s stock, valued at approximately $133,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp increased its position in Aralez Pharmaceuticals by 58.4% in the first quarter. State Street Corp now owns 790,730 shares of the company’s stock valued at $2,808,000 after buying an additional 291,595 shares in the last quarter. Geode Capital Management LLC purchased a new position in Aralez Pharmaceuticals during the first quarter valued at about $273,000. Renaissance Technologies LLC purchased a new position in Aralez Pharmaceuticals during the first quarter valued at about $2,168,000. Integre Asset Management LLC purchased a new position in Aralez Pharmaceuticals during the first quarter valued at about $291,000. Finally, Deerfield Management Co. purchased a new position in Aralez Pharmaceuticals during the first quarter valued at about $5,838,000. 49.63% of the stock is currently owned by hedge funds and other institutional investors.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) opened at 5.11 on Monday. The stock has a 50 day moving average price of $5.30 and a 200-day moving average price of $4.18. The firm’s market cap is $333.38 million. Aralez Pharmaceuticals Inc. has a 1-year low of $3.10 and a 1-year high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. Aralez Pharmaceuticals’s revenue for the quarter was up 142.3% compared to the same quarter last year. Equities research analysts forecast that Aralez Pharmaceuticals Inc. will post ($1.06) EPS for the current year.
ARLZ has been the topic of a number of analyst reports. Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Aralez Pharmaceuticals in a research note on Sunday, August 14th. Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a research note on Monday, August 15th.
In related news, Director Robert Paul Harris sold 150,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $5.82, for a total value of $873,000.00. Following the transaction, the director now directly owns 669,094 shares of the company’s stock, valued at $3,894,127.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.77% of the stock is currently owned by corporate insiders.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.